Xenon製藥 XENE 深 滬
已收盤 05-08 16:00:00 美东时间
56.44
+0.440
+0.79%
華盛通- 最 高57.47
- 今 開56.13
- 成交量 92.05万股
- 最 低 55.73
- 昨 收 56.00
- 總市值 54.55亿
- 52周最高 63.95
- 市盈率 靜 --
- 換手率 0.95%
- 52周最低 28.19
- 委 比 -90.14%
- 總股本 9664.28万
- 歷史最高 63.95
- 量 比 0.89
- 振 幅 3.11%
- 歷史最低 2.10
- 每 手 1
- 風險率 8.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xenon Pharmaceuticals Maps Path After Standout XTOL-2
Xenon Pharmaceuticals (($XENE)) has held its Q1 earnings call. Read on for the ...
05-09 09:24
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.
05-08 19:36
财报速睇 | Xenon制药 2026财年Q1营收0.00亿美元，同比下降100.0%；归母净利润亏损1.02亿美元，同比亏损扩大57.3%
华盛资讯5月8日讯，Xenon制药公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比下降100.0%，归母净利润亏损1.02亿美元，同比亏损扩大57.3%。
05-08 09:32
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals reported first...
05-08 05:50
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced on April 30, 2026, that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, after U.S. market close. A live webcast and conference call will be held at 4:30pm ET (1:30pm PT), with details available on Xenon's investor website. The company, focused on neuroscience, is advancing azetukalner, a Phase 3 K<sub>V</sub>7 potassium channel open...
04-30 20:01
Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Frequency Versus 10.4% For Placebo In Focal Onset Seizures At AAN 2026
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in the Late-breaking Science session show 53.2% reduction in monthly seizure
04-20 16:34
Xenon Expands 2025 Inducement Equity Incentive Plan
An announcement from Xenon ( ($XENE) ) is now available. On April 7, 2026, Xeno...
04-14 04:45
Xenon To Highlight Late-Breaking Science Oral And Poster Presentation Of Topline Phase 3 X-TOLE2 Study Results For Azetukalner In FOS, And Poster Presentation Of Long-Term 48-Month Azetukalner Data From X-TOLE Open Label Extension Study
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizuresPoster presentations also include long-term efficacy and
04-07 20:34
